NCT07083349

NK510 Cell Therapy for Refractory Systemic Lupus Erythematosus

An Open, Single-Center Exploratory Clinical Study of NK510 Cell Therapy for Refractory Systemic Lupus Erythematosus

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 9 (estimated)
• Sponsor: Base Therapeutics (Shanghai) Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is an investigator-initiated, open-label, single-arm study to determine safety and preliminary efficacy of NK510 for the treatment of patients with refractory systemic lupus erythematosus (SLE) in China.

Conditions

• Refractory Systemic Lupus Erythematosus

Interventions

Type	Name	Description
DRUG	NK510 : allogeneic genetic modified NK	NK510 is an allogeneic genetic modification of NK cell. NK510 will be administered at a dose of 4x10\^7 NK/kg, 8x10\^7 NK/kg and 1.2x10\^8 NK/kg by a dose-escalation design and administered IV.

Timeline

• Start date: 2025-08-01
• Primary completion: 2027-09-01
• Completion: 2027-09-01
• First posted: 2025-07-24
• Last updated: 2025-07-28